TY - JOUR
T1 - Glioblastoma y su interacción con la neurogénesis
AU - Rodríguez-Mendoza, Brenda
AU - Figueroa-González, Aura
AU - Cano-Herrera, Gabriela
AU - Gutiérrez-Rosas, Luis E.
AU - Romero-Torres, Carlos I.
AU - Victoria-García, Luis O.
AU - González-Castillo, Paola
AU - Guerrero-Cázares, Hugo
AU - Ibarra, Antonio
N1 - Publisher Copyright:
© 2024 Revista de Neurología.
PY - 2024/11/1
Y1 - 2024/11/1
N2 - Glioblastoma (GBM) is the most frequent and aggressive malignant primary tumor of the central nervous system in adults, with an incidence of 3.23 per 100,000 people. Despite the existence of various therapeutic approaches, the absence of a cure and the unfavorable prognosis persist for this neoplasm, with a median survival of approximately 8-15 months and a 5-year survival rate of 6.9%. In this review, we address the epidemiology, histopathology, molecular characteristics, and treatment of GBM. We highlight the relationship of GBM with the microenvironment in the lateral ventricle wall and the cerebrospinal fluid. The location of GBM in this region results in more aggressive tumors and shorter life expectancy for patients. Understanding the malignancy mechanisms that hinder remission, treatment, and positive prognosis opens the possibility of improving diagnostic and therapeutic interventions against GBM.
AB - Glioblastoma (GBM) is the most frequent and aggressive malignant primary tumor of the central nervous system in adults, with an incidence of 3.23 per 100,000 people. Despite the existence of various therapeutic approaches, the absence of a cure and the unfavorable prognosis persist for this neoplasm, with a median survival of approximately 8-15 months and a 5-year survival rate of 6.9%. In this review, we address the epidemiology, histopathology, molecular characteristics, and treatment of GBM. We highlight the relationship of GBM with the microenvironment in the lateral ventricle wall and the cerebrospinal fluid. The location of GBM in this region results in more aggressive tumors and shorter life expectancy for patients. Understanding the malignancy mechanisms that hinder remission, treatment, and positive prognosis opens the possibility of improving diagnostic and therapeutic interventions against GBM.
KW - Cerebrospinal fluid
KW - Epidemiology
KW - Glioblastoma
KW - Neurogenesis
KW - Subventricular zone
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85209373256&partnerID=8YFLogxK
U2 - 10.33588/rn.7910.2024226
DO - 10.33588/rn.7910.2024226
M3 - Artículo de revisión
C2 - 39540380
AN - SCOPUS:85209373256
SN - 0210-0010
VL - 79
SP - 279
EP - 287
JO - Revista de Neurologia
JF - Revista de Neurologia
IS - 10
ER -